nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—ABCG2—Vismodegib—skin cancer	0.162	0.34	CbGbCtD
Cladribine—ABCG2—Vemurafenib—skin cancer	0.128	0.269	CbGbCtD
Cladribine—ABCG2—Dactinomycin—skin cancer	0.0849	0.179	CbGbCtD
Cladribine—ABCG2—Fluorouracil—skin cancer	0.0574	0.121	CbGbCtD
Cladribine—ABCG2—Docetaxel—skin cancer	0.0439	0.0922	CbGbCtD
Cladribine—POLE2—Global Genomic NER (GG-NER)—XPA—skin cancer	0.00945	0.0769	CbGpPWpGaD
Cladribine—POLE2—Nucleotide Excision Repair—XPA—skin cancer	0.00694	0.0565	CbGpPWpGaD
Cladribine—POLE3—hair follicle—skin cancer	0.00654	0.0541	CbGeAlD
Cladribine—POLE—Global Genomic NER (GG-NER)—XPA—skin cancer	0.00609	0.0496	CbGpPWpGaD
Cladribine—POLE4—skin of body—skin cancer	0.00585	0.0484	CbGeAlD
Cladribine—POLE2—DNA Repair—POLH—skin cancer	0.00477	0.0388	CbGpPWpGaD
Cladribine—RRM2B—nipple—skin cancer	0.00469	0.0388	CbGeAlD
Cladribine—POLE2—mammalian vulva—skin cancer	0.00467	0.0386	CbGeAlD
Cladribine—POLE4—female reproductive system—skin cancer	0.00457	0.0378	CbGeAlD
Cladribine—POLE—Nucleotide Excision Repair—XPA—skin cancer	0.00447	0.0364	CbGpPWpGaD
Cladribine—POLE3—nipple—skin cancer	0.00443	0.0367	CbGeAlD
Cladribine—RRM1—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00432	0.0352	CbGpPWpGaD
Cladribine—SLC28A3—nipple—skin cancer	0.00415	0.0343	CbGeAlD
Cladribine—POLE4—head—skin cancer	0.00382	0.0316	CbGeAlD
Cladribine—POLE2—DNA Repair—XPA—skin cancer	0.00361	0.0294	CbGpPWpGaD
Cladribine—RRM2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00356	0.029	CbGpPWpGaD
Cladribine—RRM1—hair follicle—skin cancer	0.00341	0.0282	CbGeAlD
Cladribine—POLE—nipple—skin cancer	0.00338	0.028	CbGeAlD
Cladribine—NR5A1—Ovarian Infertility Genes—MLH1—skin cancer	0.00333	0.0271	CbGpPWpGaD
Cladribine—RRM2B—connective tissue—skin cancer	0.00333	0.0275	CbGeAlD
Cladribine—POLE—DNA Repair—POLH—skin cancer	0.00307	0.025	CbGpPWpGaD
Cladribine—RRM2B—mammalian vulva—skin cancer	0.00274	0.0227	CbGeAlD
Cladribine—PNP—lymphoid tissue—skin cancer	0.00262	0.0217	CbGeAlD
Cladribine—POLE3—mammalian vulva—skin cancer	0.00259	0.0214	CbGeAlD
Cladribine—PNP—female reproductive system—skin cancer	0.00253	0.0209	CbGeAlD
Cladribine—SLC28A3—mammalian vulva—skin cancer	0.00242	0.02	CbGeAlD
Cladribine—POLE2—Sorafenib—Vismodegib—skin cancer	0.0024	0.321	CbGdCrCtD
Cladribine—RRM2B—female reproductive system—skin cancer	0.00235	0.0194	CbGeAlD
Cladribine—POLE2—lymph node—skin cancer	0.00234	0.0193	CbGeAlD
Cladribine—POLE—DNA Repair—XPA—skin cancer	0.00233	0.019	CbGpPWpGaD
Cladribine—RRM1—nipple—skin cancer	0.00231	0.0191	CbGeAlD
Cladribine—POLE3—lymphoid tissue—skin cancer	0.0023	0.019	CbGeAlD
Cladribine—NR5A1—lymphoid tissue—skin cancer	0.00223	0.0184	CbGeAlD
Cladribine—POLE3—female reproductive system—skin cancer	0.00222	0.0183	CbGeAlD
Cladribine—NR5A1—female reproductive system—skin cancer	0.00215	0.0178	CbGeAlD
Cladribine—PNP—head—skin cancer	0.00211	0.0175	CbGeAlD
Cladribine—POLE—mammalian vulva—skin cancer	0.00198	0.0163	CbGeAlD
Cladribine—RRM2B—head—skin cancer	0.00196	0.0162	CbGeAlD
Cladribine—POLE2—Extension of Telomeres—TERT—skin cancer	0.00194	0.0158	CbGpPWpGaD
Cladribine—RRM2—Sorafenib—Vismodegib—skin cancer	0.00191	0.255	CbGdCrCtD
Cladribine—POLE3—head—skin cancer	0.00185	0.0153	CbGeAlD
Cladribine—PNP—Sorafenib—Vismodegib—skin cancer	0.00185	0.248	CbGdCrCtD
Cladribine—POLE2—Global Genomic NER (GG-NER)—ERCC2—skin cancer	0.00182	0.0148	CbGpPWpGaD
Cladribine—DCK—nipple—skin cancer	0.0018	0.0149	CbGeAlD
Cladribine—NR5A1—head—skin cancer	0.0018	0.0148	CbGeAlD
Cladribine—RRM2—skin of body—skin cancer	0.00178	0.0148	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—MSH2—skin cancer	0.00176	0.0143	CbGpPWpGaD
Cladribine—POLE—lymphoid tissue—skin cancer	0.00175	0.0145	CbGeAlD
Cladribine—POLA1—mammalian vulva—skin cancer	0.0017	0.0141	CbGeAlD
Cladribine—NR5A1—Ovarian Infertility Genes—CDK4—skin cancer	0.00169	0.0138	CbGpPWpGaD
Cladribine—POLE—female reproductive system—skin cancer	0.00169	0.014	CbGeAlD
Cladribine—RRM1—E2F transcription factor network—XRCC1—skin cancer	0.00166	0.0135	CbGpPWpGaD
Cladribine—RRM2—mammalian vulva—skin cancer	0.00163	0.0135	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—MLH1—skin cancer	0.00159	0.0129	CbGpPWpGaD
Cladribine—RRM1—Fluoropyrimidine Activity—ERCC2—skin cancer	0.00152	0.0124	CbGpPWpGaD
Cladribine—RRM1—skin of body—skin cancer	0.00148	0.0123	CbGeAlD
Cladribine—POLE2—Transcription-coupled NER (TC-NER)—ERCC2—skin cancer	0.00146	0.0119	CbGpPWpGaD
Cladribine—RRM2—lymphoid tissue—skin cancer	0.00144	0.0119	CbGeAlD
Cladribine—POLE2—DNA Repair—XRCC1—skin cancer	0.00144	0.0117	CbGpPWpGaD
Cladribine—RRM2B—DNA Damage Response—CDK4—skin cancer	0.00144	0.0117	CbGpPWpGaD
Cladribine—POLE—head—skin cancer	0.00141	0.0117	CbGeAlD
Cladribine—RRM2—female reproductive system—skin cancer	0.00139	0.0115	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—CDK4—skin cancer	0.00139	0.0113	CbGpPWpGaD
Cladribine—RRM2B—lymph node—skin cancer	0.00137	0.0113	CbGeAlD
Cladribine—RRM2—E2F transcription factor network—XRCC1—skin cancer	0.00137	0.0112	CbGpPWpGaD
Cladribine—RRM1—mammalian vulva—skin cancer	0.00135	0.0112	CbGeAlD
Cladribine—POLE2—Nucleotide Excision Repair—ERCC2—skin cancer	0.00134	0.0109	CbGpPWpGaD
Cladribine—ABCG2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00133	0.0108	CbGpPWpGaD
Cladribine—PNP—Paclitaxel—Docetaxel—skin cancer	0.00132	0.177	CbGdCrCtD
Cladribine—POLE3—lymph node—skin cancer	0.0013	0.0107	CbGeAlD
Cladribine—POLE2—DNA Repair—MSH2—skin cancer	0.00128	0.0104	CbGpPWpGaD
Cladribine—RRM2—Fluoropyrimidine Activity—ERCC2—skin cancer	0.00125	0.0102	CbGpPWpGaD
Cladribine—POLE—Extension of Telomeres—TERT—skin cancer	0.00125	0.0102	CbGpPWpGaD
Cladribine—RRM1—lymphoid tissue—skin cancer	0.0012	0.00992	CbGeAlD
Cladribine—POLE—Global Genomic NER (GG-NER)—ERCC2—skin cancer	0.00117	0.00956	CbGpPWpGaD
Cladribine—RRM2—head—skin cancer	0.00116	0.00962	CbGeAlD
Cladribine—RRM1—female reproductive system—skin cancer	0.00116	0.00957	CbGeAlD
Cladribine—POLE2—DNA Repair—MLH1—skin cancer	0.00115	0.00937	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00107	0.00868	CbGpPWpGaD
Cladribine—DCK—mammalian vulva—skin cancer	0.00105	0.00868	CbGeAlD
Cladribine—POLE—lymph node—skin cancer	0.00099	0.00818	CbGeAlD
Cladribine—RRM1—head—skin cancer	0.000967	0.008	CbGeAlD
Cladribine—POLE—Transcription-coupled NER (TC-NER)—ERCC2—skin cancer	0.000938	0.00764	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—XRCC1—skin cancer	0.000937	0.00763	CbGpPWpGaD
Cladribine—DCK—lymphoid tissue—skin cancer	0.000932	0.00771	CbGeAlD
Cladribine—POLE—DNA Repair—XRCC1—skin cancer	0.000927	0.00755	CbGpPWpGaD
Cladribine—DCK—female reproductive system—skin cancer	0.000899	0.00743	CbGeAlD
Cladribine—POLA1—Extension of Telomeres—TERT—skin cancer	0.00089	0.00725	CbGpPWpGaD
Cladribine—POLE2—Telomere Maintenance—TERT—skin cancer	0.000879	0.00716	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—CDK4—skin cancer	0.000878	0.00715	CbGpPWpGaD
Cladribine—POLE—Nucleotide Excision Repair—ERCC2—skin cancer	0.000862	0.00702	CbGpPWpGaD
Cladribine—POLA1—lymph node—skin cancer	0.000853	0.00705	CbGeAlD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000845	0.00688	CbGpPWpGaD
Cladribine—POLE—DNA Repair—MSH2—skin cancer	0.000822	0.0067	CbGpPWpGaD
Cladribine—RRM2—lymph node—skin cancer	0.000815	0.00674	CbGeAlD
Cladribine—DCK—head—skin cancer	0.000751	0.00621	CbGeAlD
Cladribine—POLE—DNA Repair—MLH1—skin cancer	0.000741	0.00604	CbGpPWpGaD
Cladribine—POLE2—Chromosome Maintenance—TERT—skin cancer	0.000732	0.00596	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000721	0.00587	CbGpPWpGaD
Cladribine—POLE2—DNA Repair—ERCC2—skin cancer	0.000697	0.00567	CbGpPWpGaD
Cladribine—RRM1—lymph node—skin cancer	0.000677	0.0056	CbGeAlD
Cladribine—NR5A1—Developmental Biology—SCN10A—skin cancer	0.000673	0.00548	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—CDKN2A—skin cancer	0.000671	0.00546	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000643	0.00523	CbGpPWpGaD
Cladribine—SLC22A1—head—skin cancer	0.000641	0.0053	CbGeAlD
Cladribine—RRM2B—DNA Damage Response—TP53—skin cancer	0.000611	0.00498	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000609	0.00496	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—skin cancer	0.00059	0.00481	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000587	0.00478	CbGpPWpGaD
Cladribine—ABCG2—mammalian vulva—skin cancer	0.000586	0.00484	CbGeAlD
Cladribine—POLE—Telomere Maintenance—TERT—skin cancer	0.000566	0.00461	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—CDK4—skin cancer	0.000566	0.00461	CbGpPWpGaD
Cladribine—POLE2—S Phase—CDK4—skin cancer	0.000546	0.00445	CbGpPWpGaD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—skin cancer	0.000543	0.00442	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000542	0.00441	CbGpPWpGaD
Cladribine—DCK—lymph node—skin cancer	0.000526	0.00435	CbGeAlD
Cladribine—RRM1—E2F transcription factor network—CDKN2A—skin cancer	0.000517	0.00421	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—CDK4—skin cancer	0.000507	0.00413	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000484	0.00394	CbGpPWpGaD
Cladribine—POLE—Chromosome Maintenance—TERT—skin cancer	0.000472	0.00384	CbGpPWpGaD
Cladribine—ABCG2—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000468	0.00381	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000464	0.00378	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000452	0.00368	CbGpPWpGaD
Cladribine—POLE—DNA Repair—ERCC2—skin cancer	0.000449	0.00366	CbGpPWpGaD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—skin cancer	0.000447	0.00364	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PLIN2—skin cancer	0.000438	0.00357	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—CDKN2A—skin cancer	0.000432	0.00352	CbGpPWpGaD
Cladribine—RRM2—E2F transcription factor network—CDKN2A—skin cancer	0.000425	0.00347	CbGpPWpGaD
Cladribine—POLA1—Telomere Maintenance—TERT—skin cancer	0.000403	0.00329	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—CDKN2A—skin cancer	0.000388	0.00316	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—RASA1—skin cancer	0.000386	0.00315	CbGpPWpGaD
Cladribine—PNP—Metabolism—PLIN2—skin cancer	0.00038	0.00309	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—TP53—skin cancer	0.000373	0.00304	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000362	0.00295	CbGpPWpGaD
Cladribine—Asthenia—Vemurafenib—skin cancer	0.000356	0.0013	CcSEcCtD
Cladribine—Pharyngitis—Temozolomide—skin cancer	0.000354	0.0013	CcSEcCtD
Cladribine—Chills—Dactinomycin—skin cancer	0.000354	0.0013	CcSEcCtD
Cladribine—RRM2B—Metabolism—CSPG4—skin cancer	0.000353	0.00288	CbGpPWpGaD
Cladribine—Urinary tract disorder—Temozolomide—skin cancer	0.000352	0.00129	CcSEcCtD
Cladribine—POLE—S Phase—CDK4—skin cancer	0.000352	0.00287	CbGpPWpGaD
Cladribine—Oedema peripheral—Temozolomide—skin cancer	0.000351	0.00129	CcSEcCtD
Cladribine—Cardiac failure—Docetaxel—skin cancer	0.000351	0.00129	CcSEcCtD
Cladribine—Pruritus—Vemurafenib—skin cancer	0.000351	0.00128	CcSEcCtD
Cladribine—Connective tissue disorder—Temozolomide—skin cancer	0.00035	0.00128	CcSEcCtD
Cladribine—Lethargy—Docetaxel—skin cancer	0.00035	0.00128	CcSEcCtD
Cladribine—Urethral disorder—Temozolomide—skin cancer	0.000349	0.00128	CcSEcCtD
Cladribine—Alopecia—Dactinomycin—skin cancer	0.000348	0.00128	CcSEcCtD
Cladribine—Feeling abnormal—Imiquimod—skin cancer	0.000348	0.00128	CcSEcCtD
Cladribine—Gastrointestinal pain—Imiquimod—skin cancer	0.000346	0.00127	CcSEcCtD
Cladribine—Epistaxis—Fluorouracil—skin cancer	0.000345	0.00126	CcSEcCtD
Cladribine—Erythema—Dactinomycin—skin cancer	0.000343	0.00126	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000343	0.00279	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TP53—skin cancer	0.000343	0.00279	CbGpPWpGaD
Cladribine—Pain in extremity—Docetaxel—skin cancer	0.000343	0.00126	CcSEcCtD
Cladribine—Ill-defined disorder—Bleomycin—skin cancer	0.000341	0.00125	CcSEcCtD
Cladribine—RRM2—Mitotic G1-G1/S phases—CDK4—skin cancer	0.00034	0.00277	CbGpPWpGaD
Cladribine—Anaemia—Bleomycin—skin cancer	0.00034	0.00125	CcSEcCtD
Cladribine—Diarrhoea—Vemurafenib—skin cancer	0.000339	0.00124	CcSEcCtD
Cladribine—Erythema multiforme—Temozolomide—skin cancer	0.000337	0.00123	CcSEcCtD
Cladribine—POLA1—Chromosome Maintenance—TERT—skin cancer	0.000336	0.00274	CbGpPWpGaD
Cladribine—Urticaria—Imiquimod—skin cancer	0.000336	0.00123	CcSEcCtD
Cladribine—Abdominal pain—Imiquimod—skin cancer	0.000334	0.00122	CcSEcCtD
Cladribine—Body temperature increased—Imiquimod—skin cancer	0.000334	0.00122	CcSEcCtD
Cladribine—Eye disorder—Temozolomide—skin cancer	0.000333	0.00122	CcSEcCtD
Cladribine—Malaise—Bleomycin—skin cancer	0.000332	0.00122	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000331	0.00269	CbGpPWpGaD
Cladribine—Cardiac disorder—Temozolomide—skin cancer	0.000331	0.00121	CcSEcCtD
Cladribine—Haemoglobin—Fluorouracil—skin cancer	0.00033	0.00121	CcSEcCtD
Cladribine—Haemorrhage—Fluorouracil—skin cancer	0.000329	0.0012	CcSEcCtD
Cladribine—Dizziness—Vemurafenib—skin cancer	0.000328	0.0012	CcSEcCtD
Cladribine—POLE2—Cell Cycle—MLH1—skin cancer	0.000327	0.00266	CbGpPWpGaD
Cladribine—POLE—Mitotic G1-G1/S phases—CDK4—skin cancer	0.000327	0.00266	CbGpPWpGaD
Cladribine—Pharyngitis—Fluorouracil—skin cancer	0.000326	0.00119	CcSEcCtD
Cladribine—Angiopathy—Temozolomide—skin cancer	0.000323	0.00118	CcSEcCtD
Cladribine—Ataxia—Docetaxel—skin cancer	0.000322	0.00118	CcSEcCtD
Cladribine—Immune system disorder—Temozolomide—skin cancer	0.000322	0.00118	CcSEcCtD
Cladribine—Mediastinal disorder—Temozolomide—skin cancer	0.000321	0.00118	CcSEcCtD
Cladribine—Cough—Bleomycin—skin cancer	0.000321	0.00118	CcSEcCtD
Cladribine—Chills—Temozolomide—skin cancer	0.00032	0.00117	CcSEcCtD
Cladribine—Ill-defined disorder—Dactinomycin—skin cancer	0.000318	0.00117	CcSEcCtD
Cladribine—Anaemia—Dactinomycin—skin cancer	0.000317	0.00116	CcSEcCtD
Cladribine—Vomiting—Vemurafenib—skin cancer	0.000315	0.00115	CcSEcCtD
Cladribine—Alopecia—Temozolomide—skin cancer	0.000315	0.00115	CcSEcCtD
Cladribine—Myalgia—Bleomycin—skin cancer	0.000313	0.00115	CcSEcCtD
Cladribine—Chest pain—Bleomycin—skin cancer	0.000313	0.00115	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000313	0.00255	CbGpPWpGaD
Cladribine—Rash—Vemurafenib—skin cancer	0.000313	0.00114	CcSEcCtD
Cladribine—Mental disorder—Temozolomide—skin cancer	0.000312	0.00114	CcSEcCtD
Cladribine—Dermatitis—Vemurafenib—skin cancer	0.000312	0.00114	CcSEcCtD
Cladribine—Hypersensitivity—Imiquimod—skin cancer	0.000311	0.00114	CcSEcCtD
Cladribine—Headache—Vemurafenib—skin cancer	0.000311	0.00114	CcSEcCtD
Cladribine—Malnutrition—Temozolomide—skin cancer	0.00031	0.00114	CcSEcCtD
Cladribine—Erythema—Temozolomide—skin cancer	0.00031	0.00114	CcSEcCtD
Cladribine—Discomfort—Bleomycin—skin cancer	0.000309	0.00113	CcSEcCtD
Cladribine—Malaise—Dactinomycin—skin cancer	0.000309	0.00113	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000309	0.00113	CcSEcCtD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000307	0.0025	CbGpPWpGaD
Cladribine—PNP—Metabolism—CSPG4—skin cancer	0.000306	0.00249	CbGpPWpGaD
Cladribine—Asthenia—Imiquimod—skin cancer	0.000303	0.00111	CcSEcCtD
Cladribine—Confusional state—Bleomycin—skin cancer	0.000303	0.00111	CcSEcCtD
Cladribine—Oedema—Bleomycin—skin cancer	0.0003	0.0011	CcSEcCtD
Cladribine—Back pain—Temozolomide—skin cancer	0.0003	0.0011	CcSEcCtD
Cladribine—Pruritus—Imiquimod—skin cancer	0.000299	0.0011	CcSEcCtD
Cladribine—Infection—Bleomycin—skin cancer	0.000298	0.00109	CcSEcCtD
Cladribine—Nausea—Vemurafenib—skin cancer	0.000294	0.00108	CcSEcCtD
Cladribine—Thrombocytopenia—Bleomycin—skin cancer	0.000294	0.00108	CcSEcCtD
Cladribine—Arrhythmia—Fluorouracil—skin cancer	0.000293	0.00107	CcSEcCtD
Cladribine—ABCG2—lymph node—skin cancer	0.000293	0.00243	CbGeAlD
Cladribine—Myalgia—Dactinomycin—skin cancer	0.000292	0.00107	CcSEcCtD
Cladribine—POLA1—E2F transcription factor network—CDKN2A—skin cancer	0.000291	0.00237	CbGpPWpGaD
Cladribine—Alopecia—Fluorouracil—skin cancer	0.00029	0.00106	CcSEcCtD
Cladribine—Diarrhoea—Imiquimod—skin cancer	0.000289	0.00106	CcSEcCtD
Cladribine—Discomfort—Dactinomycin—skin cancer	0.000289	0.00106	CcSEcCtD
Cladribine—Ill-defined disorder—Temozolomide—skin cancer	0.000288	0.00105	CcSEcCtD
Cladribine—Anaemia—Temozolomide—skin cancer	0.000287	0.00105	CcSEcCtD
Cladribine—Anorexia—Bleomycin—skin cancer	0.000286	0.00105	CcSEcCtD
Cladribine—Erythema—Fluorouracil—skin cancer	0.000286	0.00105	CcSEcCtD
Cladribine—Pancytopenia—Docetaxel—skin cancer	0.000281	0.00103	CcSEcCtD
Cladribine—Hypotension—Bleomycin—skin cancer	0.000281	0.00103	CcSEcCtD
Cladribine—Oedema—Dactinomycin—skin cancer	0.00028	0.00103	CcSEcCtD
Cladribine—Malaise—Temozolomide—skin cancer	0.00028	0.00102	CcSEcCtD
Cladribine—Dizziness—Imiquimod—skin cancer	0.00028	0.00102	CcSEcCtD
Cladribine—Infection—Dactinomycin—skin cancer	0.000278	0.00102	CcSEcCtD
Cladribine—Neutropenia—Docetaxel—skin cancer	0.000277	0.00101	CcSEcCtD
Cladribine—Thrombocytopenia—Dactinomycin—skin cancer	0.000274	0.001	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000274	0.001	CcSEcCtD
Cladribine—Cough—Temozolomide—skin cancer	0.000271	0.000992	CcSEcCtD
Cladribine—Paraesthesia—Bleomycin—skin cancer	0.00027	0.000987	CcSEcCtD
Cladribine—Vomiting—Imiquimod—skin cancer	0.000269	0.000984	CcSEcCtD
Cladribine—Dyspnoea—Bleomycin—skin cancer	0.000268	0.00098	CcSEcCtD
Cladribine—Anorexia—Dactinomycin—skin cancer	0.000267	0.000978	CcSEcCtD
Cladribine—Rash—Imiquimod—skin cancer	0.000267	0.000976	CcSEcCtD
Cladribine—Dermatitis—Imiquimod—skin cancer	0.000266	0.000975	CcSEcCtD
Cladribine—Pneumonia—Docetaxel—skin cancer	0.000266	0.000973	CcSEcCtD
Cladribine—Headache—Imiquimod—skin cancer	0.000265	0.00097	CcSEcCtD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000265	0.00216	CbGpPWpGaD
Cladribine—Anaemia—Fluorouracil—skin cancer	0.000264	0.000968	CcSEcCtD
Cladribine—Arthralgia—Temozolomide—skin cancer	0.000264	0.000968	CcSEcCtD
Cladribine—Myalgia—Temozolomide—skin cancer	0.000264	0.000968	CcSEcCtD
Cladribine—Infestation NOS—Docetaxel—skin cancer	0.000264	0.000967	CcSEcCtD
Cladribine—Infestation—Docetaxel—skin cancer	0.000264	0.000967	CcSEcCtD
Cladribine—Anxiety—Temozolomide—skin cancer	0.000263	0.000964	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000262	0.000961	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000262	0.000959	CcSEcCtD
Cladribine—Discomfort—Temozolomide—skin cancer	0.000261	0.000956	CcSEcCtD
Cladribine—Decreased appetite—Bleomycin—skin cancer	0.000261	0.000956	CcSEcCtD
Cladribine—RRM2—Mitotic G1-G1/S phases—CDKN2A—skin cancer	0.00026	0.00212	CbGpPWpGaD
Cladribine—Renal failure—Docetaxel—skin cancer	0.00026	0.000951	CcSEcCtD
Cladribine—Pain—Bleomycin—skin cancer	0.000257	0.00094	CcSEcCtD
Cladribine—Conjunctivitis—Docetaxel—skin cancer	0.000257	0.00094	CcSEcCtD
Cladribine—Confusional state—Temozolomide—skin cancer	0.000255	0.000935	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000255	0.000934	CcSEcCtD
Cladribine—Oedema—Temozolomide—skin cancer	0.000253	0.000928	CcSEcCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—TERT—skin cancer	0.000252	0.00205	CbGpPWpGaD
Cladribine—Infection—Temozolomide—skin cancer	0.000252	0.000922	CcSEcCtD
Cladribine—Nausea—Imiquimod—skin cancer	0.000251	0.000919	CcSEcCtD
Cladribine—POLA1—S Phase—CDK4—skin cancer	0.000251	0.00204	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.00025	0.00204	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Docetaxel—skin cancer	0.00025	0.000915	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—CDKN2A—skin cancer	0.00025	0.00203	CbGpPWpGaD
Cladribine—Epistaxis—Docetaxel—skin cancer	0.000249	0.000912	CcSEcCtD
Cladribine—Nervous system disorder—Temozolomide—skin cancer	0.000248	0.00091	CcSEcCtD
Cladribine—Thrombocytopenia—Temozolomide—skin cancer	0.000248	0.000908	CcSEcCtD
Cladribine—Feeling abnormal—Bleomycin—skin cancer	0.000247	0.000906	CcSEcCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000247	0.00201	CbGpPWpGaD
Cladribine—Skin disorder—Temozolomide—skin cancer	0.000246	0.000901	CcSEcCtD
Cladribine—Hyperhidrosis—Temozolomide—skin cancer	0.000245	0.000897	CcSEcCtD
Cladribine—Myalgia—Fluorouracil—skin cancer	0.000243	0.000892	CcSEcCtD
Cladribine—Chest pain—Fluorouracil—skin cancer	0.000243	0.000892	CcSEcCtD
Cladribine—Decreased appetite—Dactinomycin—skin cancer	0.000243	0.000892	CcSEcCtD
Cladribine—Fatigue—Dactinomycin—skin cancer	0.000241	0.000884	CcSEcCtD
Cladribine—Anorexia—Temozolomide—skin cancer	0.000241	0.000884	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—TP53—skin cancer	0.000241	0.00196	CbGpPWpGaD
Cladribine—Discomfort—Fluorouracil—skin cancer	0.000241	0.000881	CcSEcCtD
Cladribine—RRM2B—Metabolism—ENO2—skin cancer	0.00024	0.00195	CbGpPWpGaD
Cladribine—Pain—Dactinomycin—skin cancer	0.000239	0.000877	CcSEcCtD
Cladribine—Urticaria—Bleomycin—skin cancer	0.000239	0.000874	CcSEcCtD
Cladribine—Haemoglobin—Docetaxel—skin cancer	0.000238	0.000873	CcSEcCtD
Cladribine—Body temperature increased—Bleomycin—skin cancer	0.000237	0.000869	CcSEcCtD
Cladribine—Haemorrhage—Docetaxel—skin cancer	0.000237	0.000868	CcSEcCtD
Cladribine—Confusional state—Fluorouracil—skin cancer	0.000235	0.000862	CcSEcCtD
Cladribine—Pharyngitis—Docetaxel—skin cancer	0.000235	0.000862	CcSEcCtD
Cladribine—Urinary tract disorder—Docetaxel—skin cancer	0.000234	0.000857	CcSEcCtD
Cladribine—Oedema peripheral—Docetaxel—skin cancer	0.000234	0.000855	CcSEcCtD
Cladribine—Oedema—Fluorouracil—skin cancer	0.000233	0.000855	CcSEcCtD
Cladribine—Connective tissue disorder—Docetaxel—skin cancer	0.000233	0.000853	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—CDK4—skin cancer	0.000233	0.0019	CbGpPWpGaD
Cladribine—Urethral disorder—Docetaxel—skin cancer	0.000232	0.000851	CcSEcCtD
Cladribine—Infection—Fluorouracil—skin cancer	0.000232	0.000849	CcSEcCtD
Cladribine—Feeling abnormal—Dactinomycin—skin cancer	0.000231	0.000845	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000231	0.000845	CcSEcCtD
Cladribine—Insomnia—Temozolomide—skin cancer	0.000229	0.000839	CcSEcCtD
Cladribine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000229	0.000839	CcSEcCtD
Cladribine—Nervous system disorder—Fluorouracil—skin cancer	0.000229	0.000838	CcSEcCtD
Cladribine—Thrombocytopenia—Fluorouracil—skin cancer	0.000229	0.000837	CcSEcCtD
Cladribine—Tachycardia—Fluorouracil—skin cancer	0.000228	0.000834	CcSEcCtD
Cladribine—Paraesthesia—Temozolomide—skin cancer	0.000227	0.000833	CcSEcCtD
Cladribine—Dyspnoea—Temozolomide—skin cancer	0.000226	0.000827	CcSEcCtD
Cladribine—Somnolence—Temozolomide—skin cancer	0.000225	0.000825	CcSEcCtD
Cladribine—Erythema multiforme—Docetaxel—skin cancer	0.000224	0.000821	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000224	0.00182	CbGpPWpGaD
Cladribine—Anorexia—Fluorouracil—skin cancer	0.000222	0.000815	CcSEcCtD
Cladribine—Eye disorder—Docetaxel—skin cancer	0.000222	0.000811	CcSEcCtD
Cladribine—Abdominal pain—Dactinomycin—skin cancer	0.000221	0.000811	CcSEcCtD
Cladribine—Body temperature increased—Dactinomycin—skin cancer	0.000221	0.000811	CcSEcCtD
Cladribine—Hypersensitivity—Bleomycin—skin cancer	0.000221	0.00081	CcSEcCtD
Cladribine—Decreased appetite—Temozolomide—skin cancer	0.00022	0.000806	CcSEcCtD
Cladribine—Cardiac disorder—Docetaxel—skin cancer	0.00022	0.000806	CcSEcCtD
Cladribine—RRM2—Cell Cycle—MLH1—skin cancer	0.00022	0.00179	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000219	0.000801	CcSEcCtD
Cladribine—Fatigue—Temozolomide—skin cancer	0.000218	0.0008	CcSEcCtD
Cladribine—RRM1—Metabolism—PLIN2—skin cancer	0.000218	0.00178	CbGpPWpGaD
Cladribine—Hypotension—Fluorouracil—skin cancer	0.000218	0.000799	CcSEcCtD
Cladribine—Constipation—Temozolomide—skin cancer	0.000217	0.000793	CcSEcCtD
Cladribine—Pain—Temozolomide—skin cancer	0.000217	0.000793	CcSEcCtD
Cladribine—Asthenia—Bleomycin—skin cancer	0.000215	0.000789	CcSEcCtD
Cladribine—Angiopathy—Docetaxel—skin cancer	0.000215	0.000788	CcSEcCtD
Cladribine—Immune system disorder—Docetaxel—skin cancer	0.000214	0.000784	CcSEcCtD
Cladribine—Mediastinal disorder—Docetaxel—skin cancer	0.000214	0.000783	CcSEcCtD
Cladribine—Chills—Docetaxel—skin cancer	0.000213	0.000779	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000213	0.000779	CcSEcCtD
Cladribine—Pruritus—Bleomycin—skin cancer	0.000212	0.000778	CcSEcCtD
Cladribine—Arrhythmia—Docetaxel—skin cancer	0.000212	0.000776	CcSEcCtD
Cladribine—Insomnia—Fluorouracil—skin cancer	0.000211	0.000773	CcSEcCtD
Cladribine—POLE—Cell Cycle—MLH1—skin cancer	0.000211	0.00172	CbGpPWpGaD
Cladribine—Paraesthesia—Fluorouracil—skin cancer	0.00021	0.000767	CcSEcCtD
Cladribine—Alopecia—Docetaxel—skin cancer	0.00021	0.000767	CcSEcCtD
Cladribine—Feeling abnormal—Temozolomide—skin cancer	0.000209	0.000764	CcSEcCtD
Cladribine—PNP—Metabolism—ENO2—skin cancer	0.000208	0.00169	CbGpPWpGaD
Cladribine—Dyspnoea—Fluorouracil—skin cancer	0.000208	0.000762	CcSEcCtD
Cladribine—Mental disorder—Docetaxel—skin cancer	0.000208	0.000761	CcSEcCtD
Cladribine—Somnolence—Fluorouracil—skin cancer	0.000207	0.00076	CcSEcCtD
Cladribine—Gastrointestinal pain—Temozolomide—skin cancer	0.000207	0.000759	CcSEcCtD
Cladribine—Malnutrition—Docetaxel—skin cancer	0.000206	0.000756	CcSEcCtD
Cladribine—Erythema—Docetaxel—skin cancer	0.000206	0.000756	CcSEcCtD
Cladribine—Hypersensitivity—Dactinomycin—skin cancer	0.000206	0.000756	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000206	0.00168	CbGpPWpGaD
Cladribine—Decreased appetite—Fluorouracil—skin cancer	0.000203	0.000743	CcSEcCtD
Cladribine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000201	0.000738	CcSEcCtD
Cladribine—Urticaria—Temozolomide—skin cancer	0.000201	0.000737	CcSEcCtD
Cladribine—Asthenia—Dactinomycin—skin cancer	0.000201	0.000736	CcSEcCtD
Cladribine—Body temperature increased—Temozolomide—skin cancer	0.0002	0.000733	CcSEcCtD
Cladribine—Abdominal pain—Temozolomide—skin cancer	0.0002	0.000733	CcSEcCtD
Cladribine—Back pain—Docetaxel—skin cancer	0.0002	0.000731	CcSEcCtD
Cladribine—Pain—Fluorouracil—skin cancer	0.0002	0.000731	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000198	0.00161	CbGpPWpGaD
Cladribine—Feeling abnormal—Fluorouracil—skin cancer	0.000192	0.000704	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000192	0.00157	CbGpPWpGaD
Cladribine—Diarrhoea—Dactinomycin—skin cancer	0.000192	0.000702	CcSEcCtD
Cladribine—Vomiting—Bleomycin—skin cancer	0.000191	0.000699	CcSEcCtD
Cladribine—Anaemia—Docetaxel—skin cancer	0.000191	0.000699	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—CDK4—skin cancer	0.000189	0.00154	CbGpPWpGaD
Cladribine—Rash—Bleomycin—skin cancer	0.000189	0.000693	CcSEcCtD
Cladribine—Dermatitis—Bleomycin—skin cancer	0.000189	0.000693	CcSEcCtD
Cladribine—Hypersensitivity—Temozolomide—skin cancer	0.000187	0.000683	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—CDK4—skin cancer	0.000186	0.00151	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TERT—skin cancer	0.000186	0.00151	CbGpPWpGaD
Cladribine—Urticaria—Fluorouracil—skin cancer	0.000185	0.000679	CcSEcCtD
Cladribine—Body temperature increased—Fluorouracil—skin cancer	0.000184	0.000676	CcSEcCtD
Cladribine—Asthenia—Temozolomide—skin cancer	0.000182	0.000666	CcSEcCtD
Cladribine—Cough—Docetaxel—skin cancer	0.00018	0.00066	CcSEcCtD
Cladribine—RRM2—Metabolism—PLIN2—skin cancer	0.00018	0.00146	CbGpPWpGaD
Cladribine—Pruritus—Temozolomide—skin cancer	0.000179	0.000656	CcSEcCtD
Cladribine—Nausea—Bleomycin—skin cancer	0.000178	0.000653	CcSEcCtD
Cladribine—Vomiting—Dactinomycin—skin cancer	0.000178	0.000652	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—CDKN2A—skin cancer	0.000178	0.00145	CbGpPWpGaD
Cladribine—Rash—Dactinomycin—skin cancer	0.000177	0.000647	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000176	0.00144	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CSPG4—skin cancer	0.000176	0.00143	CbGpPWpGaD
Cladribine—Myalgia—Docetaxel—skin cancer	0.000176	0.000643	CcSEcCtD
Cladribine—Arthralgia—Docetaxel—skin cancer	0.000176	0.000643	CcSEcCtD
Cladribine—Chest pain—Docetaxel—skin cancer	0.000176	0.000643	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000175	0.000639	CcSEcCtD
Cladribine—Diarrhoea—Temozolomide—skin cancer	0.000173	0.000635	CcSEcCtD
Cladribine—Hypersensitivity—Fluorouracil—skin cancer	0.000172	0.00063	CcSEcCtD
Cladribine—Confusional state—Docetaxel—skin cancer	0.00017	0.000622	CcSEcCtD
Cladribine—Oedema—Docetaxel—skin cancer	0.000168	0.000617	CcSEcCtD
Cladribine—DCK—Metabolism—PLIN2—skin cancer	0.000168	0.00137	CbGpPWpGaD
Cladribine—Dizziness—Temozolomide—skin cancer	0.000168	0.000613	CcSEcCtD
Cladribine—Infection—Docetaxel—skin cancer	0.000167	0.000613	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	0.000167	0.00136	CbGpPWpGaD
Cladribine—Nausea—Dactinomycin—skin cancer	0.000166	0.000609	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CDK4—skin cancer	0.000166	0.00135	CbGpPWpGaD
Cladribine—Nervous system disorder—Docetaxel—skin cancer	0.000165	0.000605	CcSEcCtD
Cladribine—Pruritus—Fluorouracil—skin cancer	0.000165	0.000605	CcSEcCtD
Cladribine—Thrombocytopenia—Docetaxel—skin cancer	0.000165	0.000604	CcSEcCtD
Cladribine—Tachycardia—Docetaxel—skin cancer	0.000164	0.000602	CcSEcCtD
Cladribine—Skin disorder—Docetaxel—skin cancer	0.000164	0.000599	CcSEcCtD
Cladribine—Vomiting—Temozolomide—skin cancer	0.000161	0.00059	CcSEcCtD
Cladribine—Anorexia—Docetaxel—skin cancer	0.000161	0.000588	CcSEcCtD
Cladribine—Rash—Temozolomide—skin cancer	0.00016	0.000585	CcSEcCtD
Cladribine—Diarrhoea—Fluorouracil—skin cancer	0.00016	0.000585	CcSEcCtD
Cladribine—Dermatitis—Temozolomide—skin cancer	0.00016	0.000584	CcSEcCtD
Cladribine—Headache—Temozolomide—skin cancer	0.000159	0.000581	CcSEcCtD
Cladribine—Hypotension—Docetaxel—skin cancer	0.000157	0.000576	CcSEcCtD
Cladribine—Dizziness—Fluorouracil—skin cancer	0.000154	0.000565	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000153	0.000562	CcSEcCtD
Cladribine—Insomnia—Docetaxel—skin cancer	0.000152	0.000558	CcSEcCtD
Cladribine—Paraesthesia—Docetaxel—skin cancer	0.000151	0.000554	CcSEcCtD
Cladribine—Nausea—Temozolomide—skin cancer	0.00015	0.000551	CcSEcCtD
Cladribine—POLA1—Cell Cycle—MLH1—skin cancer	0.00015	0.00122	CbGpPWpGaD
Cladribine—Dyspnoea—Docetaxel—skin cancer	0.00015	0.00055	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.00015	0.00122	CbGpPWpGaD
Cladribine—Somnolence—Docetaxel—skin cancer	0.00015	0.000548	CcSEcCtD
Cladribine—Vomiting—Fluorouracil—skin cancer	0.000148	0.000543	CcSEcCtD
Cladribine—Rash—Fluorouracil—skin cancer	0.000147	0.000539	CcSEcCtD
Cladribine—Dermatitis—Fluorouracil—skin cancer	0.000147	0.000538	CcSEcCtD
Cladribine—Decreased appetite—Docetaxel—skin cancer	0.000146	0.000536	CcSEcCtD
Cladribine—Headache—Fluorouracil—skin cancer	0.000146	0.000535	CcSEcCtD
Cladribine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000145	0.000533	CcSEcCtD
Cladribine—Fatigue—Docetaxel—skin cancer	0.000145	0.000532	CcSEcCtD
Cladribine—RRM2—Metabolism—CSPG4—skin cancer	0.000145	0.00118	CbGpPWpGaD
Cladribine—Pain—Docetaxel—skin cancer	0.000144	0.000528	CcSEcCtD
Cladribine—Constipation—Docetaxel—skin cancer	0.000144	0.000528	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—CDKN2A—skin cancer	0.000142	0.00116	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000141	0.00115	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—ERCC2—skin cancer	0.000139	0.00114	CbGpPWpGaD
Cladribine—Feeling abnormal—Docetaxel—skin cancer	0.000139	0.000508	CcSEcCtD
Cladribine—Nausea—Fluorouracil—skin cancer	0.000139	0.000508	CcSEcCtD
Cladribine—Gastrointestinal pain—Docetaxel—skin cancer	0.000138	0.000504	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000136	0.00111	CbGpPWpGaD
Cladribine—DCK—Metabolism—CSPG4—skin cancer	0.000135	0.0011	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000135	0.0011	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	0.000133	0.00108	CbGpPWpGaD
Cladribine—Body temperature increased—Docetaxel—skin cancer	0.000133	0.000488	CcSEcCtD
Cladribine—Abdominal pain—Docetaxel—skin cancer	0.000133	0.000488	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CDKN2A—skin cancer	0.000127	0.00104	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000126	0.00103	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000125	0.00102	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDK4—skin cancer	0.000125	0.00102	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TERT—skin cancer	0.000125	0.00102	CbGpPWpGaD
Cladribine—Hypersensitivity—Docetaxel—skin cancer	0.000124	0.000454	CcSEcCtD
Cladribine—PNP—Metabolism—ERCC2—skin cancer	0.000121	0.000984	CbGpPWpGaD
Cladribine—Asthenia—Docetaxel—skin cancer	0.000121	0.000443	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—CDK4—skin cancer	0.00012	0.000976	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TERT—skin cancer	0.00012	0.000975	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ENO2—skin cancer	0.00012	0.000973	CbGpPWpGaD
Cladribine—Pruritus—Docetaxel—skin cancer	0.000119	0.000436	CcSEcCtD
Cladribine—NR5A1—Gene Expression—ERCC2—skin cancer	0.000116	0.000941	CbGpPWpGaD
Cladribine—Diarrhoea—Docetaxel—skin cancer	0.000115	0.000422	CcSEcCtD
Cladribine—RRM2—Cell Cycle—CDK4—skin cancer	0.000112	0.000909	CbGpPWpGaD
Cladribine—Dizziness—Docetaxel—skin cancer	0.000111	0.000408	CcSEcCtD
Cladribine—POLE—Cell Cycle—CDK4—skin cancer	0.000107	0.000873	CbGpPWpGaD
Cladribine—Vomiting—Docetaxel—skin cancer	0.000107	0.000392	CcSEcCtD
Cladribine—Rash—Docetaxel—skin cancer	0.000106	0.000389	CcSEcCtD
Cladribine—Dermatitis—Docetaxel—skin cancer	0.000106	0.000389	CcSEcCtD
Cladribine—Headache—Docetaxel—skin cancer	0.000106	0.000386	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—NRAS—skin cancer	0.000105	0.000858	CbGpPWpGaD
Cladribine—Nausea—Docetaxel—skin cancer	0.0001	0.000366	CcSEcCtD
Cladribine—RRM2—Metabolism—ENO2—skin cancer	9.84e-05	0.000801	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN2A—skin cancer	9.54e-05	0.000777	CbGpPWpGaD
Cladribine—DCK—Metabolism—ENO2—skin cancer	9.2e-05	0.000749	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN2A—skin cancer	9.16e-05	0.000746	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—KRAS—skin cancer	9.07e-05	0.000739	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDK4—skin cancer	8.54e-05	0.000695	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDKN2A—skin cancer	8.53e-05	0.000695	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TERT—skin cancer	8.53e-05	0.000695	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	8.44e-05	0.000687	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—skin cancer	8.36e-05	0.000681	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN2A—skin cancer	8.19e-05	0.000667	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—BRAF—skin cancer	8.14e-05	0.000663	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HRAS—skin cancer	7.71e-05	0.000628	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDK4—skin cancer	7.64e-05	0.000622	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—BRAF—skin cancer	7.59e-05	0.000618	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	7.5e-05	0.000611	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—IL6—skin cancer	7.38e-05	0.000601	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—skin cancer	7.25e-05	0.00059	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—skin cancer	7.07e-05	0.000576	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ERCC2—skin cancer	6.94e-05	0.000565	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PLIN2—skin cancer	6.72e-05	0.000547	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PLIN2—skin cancer	6.65e-05	0.000541	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN2A—skin cancer	6.53e-05	0.000532	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—BRAF—skin cancer	6.24e-05	0.000508	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PLIN2—skin cancer	6.2e-05	0.000505	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2A—skin cancer	5.84e-05	0.000475	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—BRAF—skin cancer	5.81e-05	0.000473	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ERCC2—skin cancer	5.72e-05	0.000466	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CSPG4—skin cancer	5.41e-05	0.000441	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CSPG4—skin cancer	5.36e-05	0.000436	CbGpPWpGaD
Cladribine—DCK—Metabolism—ERCC2—skin cancer	5.34e-05	0.000435	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CSPG4—skin cancer	4.99e-05	0.000407	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—skin cancer	4.75e-05	0.000387	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—skin cancer	4.56e-05	0.000371	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—skin cancer	4.16e-05	0.000339	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—skin cancer	3.74e-05	0.000305	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO2—skin cancer	3.68e-05	0.0003	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO2—skin cancer	3.64e-05	0.000297	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—skin cancer	3.49e-05	0.000284	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—skin cancer	3.43e-05	0.000279	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO2—skin cancer	3.39e-05	0.000276	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—skin cancer	3.25e-05	0.000264	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—skin cancer	3.2e-05	0.000261	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—skin cancer	2.87e-05	0.000234	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—skin cancer	2.67e-05	0.000218	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ERCC2—skin cancer	2.14e-05	0.000174	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ERCC2—skin cancer	2.12e-05	0.000172	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ERCC2—skin cancer	1.97e-05	0.000161	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—skin cancer	1.28e-05	0.000104	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—skin cancer	1.27e-05	0.000103	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—skin cancer	1.18e-05	9.63e-05	CbGpPWpGaD
